Aims: The present study aimed to investigate the interaction between erythrocyte phospholipid (PL) fatty acids and variants of inflammation-related genes in a Chinese population. Methods: A total of 622 patients with type 2 diabetes mellitus (T2DM) and 293 healthy subjects were included. Determination of erythrocyte PL fatty acids composition and genotyping of single nucleotide polymorphisms were conducted by standard methods. Results: A significant interaction of rs7305618 on HNFIA with C18:2n-6 and C20:4n-6 was observed: T allele carriers (TT + CT) had a higher risk of T2DM than noncarriers only when they had a higher level of C18:2n-6 or C20:4n-6, and the odds ratios (ORs) were 2.59 (95% CI 1.58-4.24; p for interaction = 0.005) and 2.49 (95% CI 1.47-4.24; p for interaction = 0.021), respectively. A significant interaction of rs8078723 at the intergenic region between PSMD3 and CSF3 with C20:5n-3 was observed: C allele carriers (CC + CT) had a lower risk of T2DM than noncarriers only when they had a higher level of C20:5n-3, and the OR was 0.44 (95% CI 0.26-0.73; p for interaction = 0.014). Conclusions: rs7305618 and rs8078723 were associated with the risk of T2DM in a Chinese population and were modulated by erythrocyte PL fatty acids composition.

Keywords:
Type 2 diabetes mellitus, Single nucleotide polymorphism, Polyunsaturated fatty acids, Inflammation
1.
Arisawa K, Uemura H, Yamaguchi M, Nakamoto M, Hiyoshi M, Sawachika F, Katsuura-Kamano S: Associations of dietary patterns with metabolic syndrome and insulin resistance: a cross-sectional study in a Japanese population. J Med Invest 2014;61:333-344.
2.
Huang T, Wahlqvist ML, Xu TC, Xu A, Zhang AZ, Li D: Increased plasma n-3 polyunsaturated fatty acid is associated with improved insulin sensitivity in type 2 diabetes in China. Mol Nutr Food Res 2010;54:S112-S119.
3.
Zheng JS, Huang T, Yang J, Fu YQ, Li D: Marine n-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in Asians: a systematic review and meta-analysis. PLoS One 2012;7:e44525.
4.
Cormier H, Rudkowska I, Thifault E, Lemieux S, Couture P, Vohl MC: Polymorphisms in fatty acid desaturase (FADS) gene cluster: effects on glycemic controls following an omega-3 polyunsaturated fatty acids (PUFA) supplementation. Genes 2013;4:485-498.
5.
Fisher E, Schreiber S, Joost HG, Boeing H, Doring F: A two-step association study identifies CAV2 rs2270188 single nucleotide polymorphism interaction with fat intake in type 2 diabetes risk. J Nutr 2011;141:177-181.
6.
Lee YC, Lai CQ, Ordovas JM, Parnell LD: A database of gene-environment interactions pertaining to blood lipid traits, cardiovascular disease and type 2 diabetes. J Data Mining Genomics Proteomics 2011;2:106.
7.
Marin C, Perez-Martinez P, Delgado-Lista J, Gomez P, Rodriguez F, Yubero-Serrano EM, Garcia-Rios A, Camargo A, Perez-Jimenez F, Lopez-Miranda J: The insulin sensitivity response is determined by the interaction between the G972R polymorphism of the insulin receptor substrate 1 gene and dietary fat. Mol Nutr Food Res 2011;55:328-335.
8.
Perez-Martinez P, Lopez-Miranda J, Cruz-Teno C, Delgado-Lista J, Jimenez-Gomez Y, Fernandez JM, Gomez MJ, Marin C, Perez-Jimenez F, Ordovas JM: Adiponectin gene variants are associated with insulin sensitivity in response to dietary fat consumption in Caucasian men. J Nutr 2008;138:1609-1614.
9.
Ruchat SM, Elks CE, Loos RJF, Vohl MC, Weisnagel SJ, Rankinen T, Bouchard C, Perusse L: Evidence of interaction between type 2 diabetes susceptibility genes and dietary fat intake for adiposity and glucose homeostasis-related phenotypes. J Nutrigenet Nutrigenomics 2009;2:225-234.
10.
Huang T, Sun J, Chen Y, Xie H, Xu D, Li D: Associations of common variants in methionine metabolism pathway genes with plasma homocysteine and the risk of type 2 diabetes in Han Chinese. J Nutrigenet Nutrigenomics 2014;7:63-74.
11.
Andrews GM, Arredondo OM: Association between ferritin, high sensitivity C-reactive protein (hsCRP) and relative abundance of hepcidin mRNA with the risk of type 2 diabetes in obese subjects. Nutr Hosp 2013;30:577-584.
12.
Brooks-Worrell B, Palmer JP: Immunology in the clinic review series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012;167:40-46.
13.
Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
14.
Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO, O'Reilly DS, Packard CJ, Sattar N; West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-1600.
15.
Gkrania-Klotsas E, Ye Z, Cooper AJ, Sharp SJ, Luben R, Biggs ML, Chen LK, Gokulakrishnan K, Hanefeld M, Ingelsson E, Lai WA, Lin SY, Lind L, Lohsoonthorn V, Mohan V, Muscari A, Nilsson G, Ohrvik J, Chao Qiang J, Jenny NS, Tamakoshi K, Temelkova-Kurktschiev T, Wang YY, Yajnik CS, Zoli M, Khaw KT, Forouhi NG, Wareham NJ, Langenberg C: Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PLoS One 2010;5:e13405.
16.
Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS: Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
17.
Kong M, Lee C: Genetic associations with C-reactive protein level and white blood cell count in the KARE study. Int J Immunogenet 2013;40:120-125.
18.
Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Chauhan G, Ghosh S, Tandon N, Bharadwaj D: Common variants in CRP and LEPR influence high sensitivity C-reactive protein levels in North Indians. PLoS One 2011;6:e24645.
19.
Wu Y, McDade TW, Kuzawa CW, Borja J, Li Y, Adair LS, Mohlke KL, Lange LA: Genome-wide association with C-reactive protein levels in CLHNS: evidence for the CRP and HNF1A loci and their interaction with exposure to a pathogenic environment. Inflammation 2012;35:574-583.
20.
Li K, Huang T, Zheng J, Wu K, Li D: Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor alpha: a meta-analysis. PLoS One 2014;9:e88103.
21.
Huang T, Sun JQ, Chen YQ, Xie H, Xu DF, Huang JY, Li D: Genetic variants in desaturase gene, erythrocyte fatty acids, and risk for type 2 diabetes in Chinese Hans. Nutrition 2014;30:897-902.
22.
James AT: Qualitative and quantitative determination of the fatty acids by gas-liquid chromatography. Methods Biochem Anal 1960;8:1-59.
23.
Zheng JS, Arnett DK, Parnell LD, Lee YC, Ma YY, Smith CE, Richardson K, Li D, Borecki IB, Ordovas JM, Tucker KL, Lai CQ: Genetic variants at PSMD3 interact with dietary fat and carbohydrate to modulate insulin resistance. J Nutr 2013;143:354-361.
24.
Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, Pankow JS, Song Q: Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI family heart study. Am J Physiol Heart Circ Physiol 2006;291:H2752-H2757.
25.
Li SP, Goldman ND: Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996;35:9060-9068.
26.
Morita K, Saruwatari J, Tanaka T, Oniki K, Kajiwara A, Otake K, Ogata Y, Nakagawa K: Associations between the common HNF1A gene variant p.I27l (rs1169288) and risk of type 2 diabetes mellitus are influenced by weight. Diabetes Metab 2015;41:91-94.
27.
Wakil SM, Muiya NP, Tahir AI, Al-Najai M, Baz B, Andres E, Mazhar N, Al Tassan N, Alshahid M, Meyer BF, Dzimiri N: A new susceptibility locus for myocardial infarction, hypertension, type 2 diabetes mellitus, and dyslipidemia on chromosome 12q24. Dis Markers 2014;2014:291419.
28.
Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI, Walston JD, Cooper GM, Jenny NS, Rieder MJ, Durda JP, Smith JD, Novembre J, Tracy RP, Rotter JI, Stephens M, Nickerson DA, Krauss RM: Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008;82:1193-1201.
29.
Williams K, Higgs G: Eicosanoids and inflammation. J Pathol 1988;156:101-110.
30.
Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:S1505-S1519.
31.
Wallis JG, Watts JL: Polyunsaturated fatty acid synthesis: what will they think of next? Trends Biochem Sci 2002;27:467-473.
32.
Brender E, Lynm C, Glass RM: Granulocyte-colony stimulating factor. JAMA 2006;295:1088.
33.
Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
34.
Rome S, Meugnier E, Vidal H: The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling. Curr Opin Clin Nutr Metab Care 2004;7:249-254.
35.
Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, Quigg RJ: Microrna-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008;22:4126-4135.
36.
Hamel FG, Fawcett J, Bennett RG, Duckworth WC: Control of proteolysis: hormones, nutrients, and the changing role of the proteasome. Curr Opin Clin Nutr Metab Care 2004;7:255-258.
37.
Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (irs-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230-50236.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.